NASDAQ:ARGX

argenex (ARGX) Stock Price, News & Analysis

argenex logo
$947.88 -3.07 (-0.32%)
Closing price 03:59 PM Eastern
Extended Trading
$947.56 -0.31 (-0.03%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About argenex Stock (NASDAQ:ARGX)

Advanced

Key Stats

Today's Range
$934.66
▼
$952.37
50-Day Range
$802.64
▼
$1,007.07
52-Week Range
$661.85
▼
$1,072.75
Volume
370,300 shs
Average Volume
352,642 shs
Market Capitalization
$59.61 billion
P/E Ratio
33.07
Dividend Yield
N/A
Price Target
$1,163.18
Consensus Rating
Moderate Buy

Company Overview

argenx SE is a global immunology company focused on developing medicines for autoimmune diseases. Founded in 2008 and headquartered in the Netherlands, the company uses antibody engineering and other research approaches to identify and develop treatments for conditions with significant unmet medical needs.

Its lead medicine is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo. These products target the neonatal Fc receptor (FcRn) and are approved in the United States for certain patients with generalized myasthenia gravis; Vyvgart Hytrulo is also approved for chronic inflammatory demyelinating polyneuropathy. argenx continues to study efgartigimod in additional diseases and develop other potential therapies.

argenx operates internationally, with commercial activities and research collaborations across multiple markets. Tim Van Hauwermeiren is the company’s chief executive officer.

AI Generated. May Contain Errors.

argenex Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
91st Percentile Overall Score

ARGX MarketRank™: 
4.573550868815 of 5 stars

argenex scored higher than 91% of companies evaluated by MarketBeat, and ranked 28th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    argenex has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 1 strong buy rating, 21 buy ratings, 6 hold ratings, and no sell ratings.

  • Upside Potential

    argenex has a consensus price target of $1,163.18, representing about 22.8% upside from its current price of $947.08.

  • Amount of Analyst Coverage

    argenex has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about argenex's stock forecast and price target.
  • Earnings Growth

    Earnings for argenex are expected to grow by 24.53% in the coming year, from $28.41 to $35.38 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of argenex is 32.99, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.99.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of argenex is 32.99, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.18.

  • Price to Earnings Growth Ratio

    argenex has a PEG Ratio of 0.91. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    argenex has a P/B Ratio of 8.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.30% of the float of argenex has been sold short.
  • Short Interest Ratio / Days to Cover

    argenex has a short interest ratio ("days to cover") of 3.42, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in argenex has recently increased by 4.34%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    argenex does not currently pay a dividend.

  • Dividend Growth

    argenex does not have a long track record of dividend growth.

  • News Sentiment

    argenex has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for argenex this week, compared to 7 articles on an average week.
  • Search Interest

    Only 3 people have searched for ARGX on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
  • MarketBeat Follows

    Only 5 people have added argenex to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, argenex insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    2.43% of the stock of argenex is held by insiders.

  • Percentage Held by Institutions

    60.32% of the stock of argenex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about argenex's insider trading history.
Receive ARGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for argenex and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ARGX Stock News Headlines

argenex (NASDAQ:ARGX) Stock Gets Price Target Reduction from Morgan Stanley
My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
argenx: Unnatural Products Deal Changes Risk Profile
See More Headlines

ARGX Stock Analysis - Frequently Asked Questions

argenex's stock was trading at $840.95 at the start of the year. Since then, ARGX shares have increased by 12.6% and is now trading at $947.0810.

argenex SE (NASDAQ:ARGX) posted its quarterly earnings data on Friday, October, 23rd. The company reported $7.80 earnings per share for the quarter, beating the consensus estimate of $7.44 by $0.36. The firm had revenue of $1.75 billion for the quarter. argenex had a net margin of 31.66% and a trailing twelve-month return on equity of 47.70%.
Read the conference call transcript
.

argenex (ARGX) raised $97 million in an initial public offering (IPO) on Thursday, May 18th 2017. The company issued 5,865,000 shares at $16.62 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

argenex's top institutional shareholders include Bellevue Group AG (0.46%), Bessemer Group Inc. (0.42%), William Blair Investment Management LLC (0.39%) and Checkpoint Capital L.P. (0.29%).

Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that argenex investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Broadcom (AVGO), Palantir Technologies (PLTR), Palo Alto Networks (PANW) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
10/23/2026
Today
11/17/2026
Jefferies Global Healthcare Conference
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ARGX
Previous Symbol
NASDAQ:ARGX
CIK
1697862
Fax
N/A
Employees
1,863
Year Founded
2008

Price Target and Rating

High Price Target
$1,400.00
Low Price Target
$861.00
Potential Upside/Downside
+23.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
28 Analysts

Profitability

EPS (Trailing Twelve Months)
$28.66
Trailing P/E Ratio
32.85
Forward P/E Ratio
26.61
P/E Growth
0.91
Net Income
$1.29 billion
Net Margins
31.66%
Pretax Margin
32.04%
Return on Equity
47.70%
Return on Assets
40.12%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.12
Quick Ratio
4.89

Sales & Book Value

Annual Sales
$5.82 billion
Price / Sales
10.17
Cash Flow
$20.47 per share
Price / Cash Flow
46.00
Book Value
$118.34 per share
Price / Book
7.96

Miscellaneous

Outstanding Shares
62,886,000
Free Float
61,358,000
Market Cap
$59.21 billion
Optionable
Optionable
Beta
0.48

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:ARGX) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners